Reporting to the Chief Scientific Officer, this role leads DMPK and bioanalytical strategy across nonclinical and clinical programs, operating as a hands-on scientific leader. We are looking for an accomplished DMPK and bioanalytical scientist with experience in PK study design, bioanalytical method development, and translational biomarker strategy. This person will support pharmacology and nonclinical toxicology programs, providing broader context across the nonclinical development portfolio.

Responsibilities

Lead DMPK and bioanalytical strategy across nonclinical and clinical programs, including PK, biomarker, and translational PD readouts Lead method development, qualification, and validation for bioanalytical assays (GLP/GCP-compliant as required) Design, execute, and oversee PK and PK-PD studies of tRNAs to evaluate delivery technologies (LNP and others) and biomarker effects Manage and qualify CRO and external lab partners across bioanalytical and PK programs Support nonclinical toxicology programs in collaboration with internal teams and CROs Analyze, interpret, and present DMPK and translational biomarker data to internal leadership and external stakeholders Author nonclinical sections of regulatory filings (e.g., IND) and briefing documents; support agency interactions and responses Serve on the Research Leadership Team; represent DMPK and bioanalytical sciences in cross-functional program discussions Manage and develop direct report(s); collaborate with the broader pharmacology team

Required Qualifications

Preferred Qualifications

Experience in rare disease, genetic medicine, or nucleic acid / RNA therapeutics Familiarity with LNP platform biology and delivery landscape Familiarity with GLP toxicology study design and ICH nonclinical guidelines Experience operating in a cross-functional leadership role at a clinical-stage biotech Experience with LC-MS/MS or related mass spectrometry platforms About Alltrna Alltrna is the first clinical-stage biotech company advancing tRNA medicines to address shared disease-causing mutations across many indications. The company’s initial therapeutic programs are designed to restore full-length protein production in diseases caused by premature termination codons (PTCs), collectively referred to as Stop Codon Disease, which affects approximately 10% of people with a rare genetic disease. Alltrna’s lead program, AP003, is a chemically modified, engineered tRNA oligonucleotide encapsulated in a clinically validated, liver-directed lipid nanoparticle.

AP003 is being developed for the arginine-to-TGA (Arg-TGA) PTC in patients with liver Stop Codon Disease, including phenylketonuria, organic acidemias, and urea cycle disorders.

Sr. Principal Scientist / Director, DMPK & Bioanalytical Sciences